{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:08:13Z","timestamp":1784531293694,"version":"3.55.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.eprac.2026.01.753","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:47:49Z","timestamp":1770943669000},"page":"795-802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Aging With Cystic Fibrosis: Endocrine and Metabolic Considerations"],"prefix":"10.1016","volume":"32","author":[{"given":"Katie","family":"Kaput","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Steinmetz-Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa S.","family":"Putman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5206-4965","authenticated-orcid":false,"given":"Heidi","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.eprac.2026.01.753_bib1","first-page":"S5","article-title":"Increasing life expectancy in cystic fibrosis: advances and challenges","volume":"57","author":"McBennett","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.eprac.2026.01.753_bib2","series-title":"Patient Registry 2023 Annual Data Report","year":"2024"},{"key":"10.1016\/j.eprac.2026.01.753_bib3","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1515\/jpem-2019-0484","article-title":"Cystic fibrosis-related diabetes: an update on pathophysiology, diagnosis, and treatment","volume":"33","author":"Alves","year":"2020","journal-title":"J Pediatr Endocrinol Metab JPEM"},{"key":"10.1016\/j.eprac.2026.01.753_bib4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.10.009","article-title":"Cystic fibrosis related diabetes in Europe: prevalence, risk factors and outcome; Olesen","volume":"19","author":"Olesen","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jcf.2011.10.005","article-title":"Diabetes mellitus and survival in cystic fibrosis patients after lung transplantation","volume":"11","author":"Hofer","year":"2012","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1399-0012.2005.00420.x","article-title":"Incidence and prevalence of diabetes mellitus in patients with cystic fibrosis undergoing lung transplantation before and after lung transplantation","volume":"19","author":"Hadjiliadis","year":"2005","journal-title":"Clin Transpl"},{"key":"10.1016\/j.eprac.2026.01.753_bib7","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1210\/clinem\/dgae857","article-title":"Glycemia and insulin secretion in cystic fibrosis 2 years after Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"110","author":"Chan","year":"2025","journal-title":"PROMISE-ENDO. J Clin Endocrinol Metab."},{"key":"10.1016\/j.eprac.2026.01.753_bib8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1164\/rccm.201806-1018OC","article-title":"Islet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy","volume":"199","author":"Kelly","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eprac.2026.01.753_bib9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib10","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.01.753_bib11","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.2337\/dc06-0654","article-title":"Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications","volume":"29","author":"Andersen","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.01.753_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jcf.2008.05.008","article-title":"Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD)","volume":"7","author":"van den Berg","year":"2008","journal-title":"J Cyst"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2026.01.753_bib13","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jcf.2019.08.004","article-title":"Hypoglycemia in cystic fibrosis: prevalence, impact and treatment","volume":"18","author":"Moheet","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib14","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41574-021-00512-2","article-title":"Type 2 diabetes mellitus in older adults: clinical considerations and management","volume":"17","author":"Bellary","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.eprac.2026.01.753_bib15","first-page":"1341","article-title":"Altered responses to hypoglycemia of healthy elderly people","volume":"78","author":"Meneilly","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.01.753_bib16","doi-asserted-by":"crossref","first-page":"b4909","DOI":"10.1136\/bmj.b4909","article-title":"The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study","volume":"340","author":"Bonds","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2026.01.753_bib17","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.2337\/dc20-0316","article-title":"Severe hypoglycemia and risk of falls in type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study","volume":"43","author":"Lee","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.01.753_bib18","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/j.jcf.2016.09.010","article-title":"Coronary artery disease in cystic fibrosis: an emerging concern?","volume":"15","author":"Skolnik","year":"2016","journal-title":"J Cyst"},{"key":"10.1016\/j.eprac.2026.01.753_bib19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jcf.2021.04.016","article-title":"Cardiovascular complications in cystic fibrosis: a review of the literature","volume":"21","author":"Poore","year":"2022","journal-title":"J Cyst"},{"key":"10.1016\/j.eprac.2026.01.753_bib20","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.2337\/dc25-S013","article-title":"13. Older adults: standards of care in Diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.01.753_bib21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.7326\/M14-0737","article-title":"Diabetes in midlife and cognitive change over 20 years: a cohort study","volume":"161","author":"Rawlings","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eprac.2026.01.753_bib22","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/archneurol.2012.1117","article-title":"Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia","volume":"69","author":"Yaffe","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.eprac.2026.01.753_bib23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jcf.2021.04.014","article-title":"Cystic fibrosis-related diabetes (CFRD) and cognitive function in adults with cystic fibrosis","volume":"21","author":"Chadwick","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/dme.13652","article-title":"Unique challenges of cystic fibrosis-related diabetes","author":"Bridges","year":"2018","journal-title":"Diabet Med J Br Diabet Assoc"},{"key":"10.1016\/j.eprac.2026.01.753_bib25","series-title":"Patient Registry Highlights","year":"2025"},{"key":"10.1016\/j.eprac.2026.01.753_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jcf.2022.07.013","article-title":"Continuous glucose monitoring versus self-monitoring of blood glucose in the management of cystic fibrosis related diabetes: a systematic review and meta-analysis","volume":"22","author":"Kumar","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib27","first-page":"753","article-title":"Perceptions of diabetes technology use in cystic fibrosis-related diabetes management","volume":"23","author":"Marks","year":"2021","journal-title":"Diabetes Technol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2026.01.753_bib28","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jcf.2019.08.025","article-title":"Continuous glucose monitoring in cystic fibrosis - a practical guide","volume":"18","author":"Chan","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib29","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jcf.2019.01.009","article-title":"The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity","volume":"18","author":"Colomba","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib30","article-title":"Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: a cases series and literature review","volume":"38","author":"Ahmed","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.eprac.2026.01.753_bib31","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/dom.13544","article-title":"Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: a randomized crossover trial","volume":"21","author":"Geyer","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.01.753_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(25)02300-8","article-title":"684 Efficacy and safety of GLP-1 agonist therapy in overweight and obese subjects with cystic fibrosis-related diabetes: a pilot study","volume":"24","author":"Moheet","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib33","article-title":"Impact of glucagon-like-peptide-1 receptor agonist therapy on pulmonary function in people with cystic fibrosis who achieve normal body mass index","author":"Horvit","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib34","doi-asserted-by":"crossref","first-page":"e3673","DOI":"10.1002\/dmrr.3673","article-title":"Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: a systematic review and network meta-analysis","volume":"39","author":"Tian","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.eprac.2026.01.753_bib35","article-title":"Treatment of cystic fibrosis related bone disease","volume":"27","author":"Ullal","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.eprac.2026.01.753_bib36","doi-asserted-by":"crossref","unstructured":"Bianchi M.L., Romano G., Saraifoger S., Costantini D., Limonta C. Colombo C. BMD and body composition in children and young patients affected by cystic fibrosis. J Bone Miner Res. 2006;21:388\u2013396.","DOI":"10.1359\/JBMR.051106"},{"key":"10.1016\/j.eprac.2026.01.753_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10666","article-title":"Prevalence and risk factors for low bone mineral density in adults with cystic fibrosis","volume":"6","author":"Boyle","year":"2022","journal-title":"JBMR Plus"},{"key":"10.1016\/j.eprac.2026.01.753_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-009-9316-9","article-title":"The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis","volume":"86","author":"Paccou","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.eprac.2026.01.753_bib39","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1093\/jbmr\/zjae139","article-title":"Longitudinal changes in BMD in adults with cystic fibrosis","volume":"39","author":"Jad","year":"2024","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eprac.2026.01.753_bib40","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1210\/jc.2004-1629","article-title":"Guide to bone health and disease in cystic fibrosis","volume":"90","author":"Aris","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.01.753_bib41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1471-2474-9-125","article-title":"Longitudinal analysis of vertebral fracture and BMD in a Canadian cohort of adult cystic fibrosis patients","volume":"9","author":"Papaioannou","year":"2008","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.eprac.2026.01.753_bib42","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jcf.2016.06.004","article-title":"Multiple prevalent fractures in relation to macroscopic bone architecture in patients with cystic fibrosis","volume":"17","author":"Stahl","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib43","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12877-016-0332-0","article-title":"A critical review of the long-term disability outcomes following hip fracture","volume":"16","author":"Dyer","year":"2016","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.eprac.2026.01.753_bib44","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1001\/archinternmed.2011.447","article-title":"Hip fracture and increased short-term but not long-term mortality in healthy older women","volume":"171","author":"LeBlanc","year":"2011","journal-title":"Arch Intern Med"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2026.01.753_bib45","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1569-1993(11)60004-0","article-title":"European cystic fibrosis bone mineralisation guidelines","volume":"10","author":"Sermet-Gaudelus","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib46","article-title":"Bisphosphonates for osteoporosis in people with cystic fibrosis","volume":"1","author":"Jeffery","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eprac.2026.01.753_bib47","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.amjms.2022.04.018","article-title":"Romosozumab used to treat a patient with cystic fibrosis-related osteoporosis","volume":"364","author":"Crow","year":"2022","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.eprac.2026.01.753_bib48","article-title":"Teriparatide as treatment for severe osteoporosis in lung transplant recipients","volume":"2","author":"Raven","year":"2024","journal-title":"JCEM Case Rep"},{"key":"10.1016\/j.eprac.2026.01.753_bib49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ppul.26243","article-title":"Effect of Trikafta on bone density, body composition and exercise capacity in CF: a pilot study","volume":"58","author":"Gur","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.eprac.2026.01.753_bib50","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa890","article-title":"The effects of ivacaftor on bone density and microarchitecture in children and adults with cystic fibrosis","volume":"106","author":"Putman","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.01.753_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71280","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor effect on bone density and body composition: a retrospective analysis","volume":"60","author":"Trost","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.eprac.2026.01.753_bib52","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf149.588","article-title":"SAT-732 longitudinal changes in bone mineral density after initiation of elexacaftor-tezacaftor-ivacaftor in youth and adults with cystic fibrosis","volume":"9","author":"Bezerra","year":"2025","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.eprac.2026.01.753_bib53","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.eprac.2025.04.011","article-title":"Menopause in cystic fibrosis: special considerations for bone health, menopausal symptoms, and treatment","volume":"31","author":"Haroon","year":"2025","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2026.01.753_bib54","series-title":"StatPearls","article-title":"Menopause","author":"Peacock","year":"2025"},{"key":"10.1016\/j.eprac.2026.01.753_bib55","first-page":"401","volume":"30","author":"Prochownik","year":"2023","journal-title":"Menopause in people with cystic fibrosis"},{"key":"10.1016\/j.eprac.2026.01.753_bib56","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jcf.2024.01.005","article-title":"Standards for the care of people with Cystic Fibrosis (CF); recognising and addressing CF health issues","volume":"23","author":"Burgel","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib57","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ecl.2015.05.001","article-title":"Menopausal symptoms and their management","volume":"44","author":"Santoro","year":"2015","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.eprac.2026.01.753_bib58","doi-asserted-by":"crossref","first-page":"458","DOI":"10.5114\/aoms\/157308","article-title":"Menopause and women\u2019s cardiovascular health: is it really an obvious relationship?","volume":"19","author":"Ryczkowska","year":"2023","journal-title":"Arch Med Sci AMS"},{"key":"10.1016\/j.eprac.2026.01.753_bib59","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/13697137.2015.1020484","article-title":"Long-term health consequences of premature or early menopause and considerations for management","volume":"18","author":"Faubion","year":"2015","journal-title":"Climacteric J Int Menopause Soc"},{"key":"10.1016\/j.eprac.2026.01.753_bib60","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.tem.2012.03.008","article-title":"Estrogen and the skeleton","volume":"23","author":"Khosla","year":"2012","journal-title":"Trends Endocrinol Metab TEM"},{"key":"10.1016\/j.eprac.2026.01.753_bib61","first-page":"9","article-title":"Primary osteoporosis in postmenopausal women","volume":"1","author":"Ji","year":"2015","journal-title":"Chronic Dis Transl Med"},{"key":"10.1016\/j.eprac.2026.01.753_bib62","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1164\/rccm.201605-0968OC","article-title":"Menopause is associated with accelerated lung function decline","volume":"195","author":"Triebner","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eprac.2026.01.753_bib63","article-title":"Lung function changes across the menopausal transition: a longitudinal analysis of annual examinations","author":"Imai","year":"2025","journal-title":"CHEST"},{"key":"10.1016\/j.eprac.2026.01.753_bib64","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaci.2015.08.019","article-title":"Menopause as a predictor of new-onset asthma: a longitudinal Northern European population study","volume":"137","author":"Triebner","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.eprac.2026.01.753_bib65","doi-asserted-by":"crossref","first-page":"659","DOI":"10.31616\/asj.2020.0082","article-title":"The influence of restrictive pulmonary dysfunction on osteoporotic thoracic vertebral fractures","volume":"15","author":"Park","year":"2021","journal-title":"Asian Spine J"},{"key":"10.1016\/j.eprac.2026.01.753_bib66","article-title":"Use of estrogen supplementation is associated with higher quality of life scores in women with cystic fibrosis","volume":"27","author":"Wu","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.eprac.2026.01.753_bib67","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01253-2023","article-title":"Cystic fibrosis and the cardiovascular system: the unexpected heartache","volume":"62","author":"Hebestreit","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.eprac.2026.01.753_bib68","doi-asserted-by":"crossref","DOI":"10.1513\/AnnalsATS.202502-170OC","article-title":"Elevated rates and earlier onset of non-pulmonary comorbidities in adults with cystic fibrosis: a population-based study","author":"Arya","year":"2025","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.eprac.2026.01.753_bib69","doi-asserted-by":"crossref","first-page":"2300174","DOI":"10.1183\/13993003.00174-2023","article-title":"Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: a multinational retrospective cohort study","volume":"62","author":"Frost","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.eprac.2026.01.753_bib70","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1183\/09031936.00060007","article-title":"Expression and function of cystic fibrosis transmembrane conductance regulator in rat intrapulmonary arteries","volume":"30","author":"Robert","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.eprac.2026.01.753_bib71","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0008-6363(95)00245-6","article-title":"CFTR chloride channels in human and simian heart","volume":"31","author":"Warth","year":"1996","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.eprac.2026.01.753_bib72","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jcf.2015.06.003","article-title":"The impact of cystic fibrosis transmembrane regulator disruption on cardiac function and stress response","volume":"15","author":"Jiang","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib73","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1113\/jphysiol.2010.188334","article-title":"Cardiomyocytes with disrupted CFTR function require CaMKII and Ca(2+)-activated Cl(-) channel activity to maintain contraction rate","volume":"588","author":"Sellers","year":"2010","journal-title":"J Physiol"},{"key":"10.1016\/j.eprac.2026.01.753_bib74","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jcf.2024.09.012","article-title":"Cardiac structure and function in people with cystic fibrosis","volume":"23","author":"Duus","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib75","article-title":"Cardiovascular system involvement in cystic fibrosis","volume":"13","author":"Shah","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.eprac.2026.01.753_bib76","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: interim results of an open-label phase 3 clinical trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eprac.2026.01.753_bib77","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib78","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of Elexacaftor-Tezacaftor-Ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e15756","article-title":"Elexacaftor - Tezacaftor - Ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study","volume":"9","author":"Schnell","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.eprac.2026.01.753_bib80","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jcf.2023.01.004","article-title":"Improved glucose tolerance after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in adults with cystic fibrosis","volume":"22","author":"Steinack","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib81","first-page":"457","article-title":"Use of the latent image technique to develop and evaluate problem-solving skills","volume":"41","author":"Schwabbauer","year":"1975","journal-title":"Am J Med Technol"},{"key":"10.1016\/j.eprac.2026.01.753_bib82","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD Clinical Practice Consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.eprac.2026.01.753_bib83","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251317200","article-title":"New era, new GOALs: cardiovascular screening and lipid management in cystic fibrosis","volume":"19","author":"Despotes","year":"2025","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.eprac.2026.01.753_bib84","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jama.287.8.1003","article-title":"Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart study","volume":"287","author":"Vasan","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.eprac.2026.01.753_bib85","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jcf.2022.04.010","article-title":"Onset of systemic arterial hypertension after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in adults with cystic fibrosis: a case series","volume":"21","author":"Gramegna","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib86","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.01.753_bib87","doi-asserted-by":"crossref","DOI":"10.52225\/narra.v4i1.533","article-title":"Positive correlation between body weight and body mass index with blood pressure in young adults","volume":"4","author":"Yusni","year":"2024","journal-title":"Narra J"},{"key":"10.1016\/j.eprac.2026.01.753_bib88","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jcf.2019.04.001","article-title":"Cystic fibrosis dyslipidaemia: a cross-sectional study","volume":"18","author":"Nowak","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib89","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jcf.2023.07.001","article-title":"Improvement of lipid and lipoprotein profiles in children and adolescents with cystic fibrosis on CFTR modulator therapy","volume":"22","author":"Yuzyuk","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib90","first-page":"100308","article-title":"Coronary artery disease in patients with cystic fibrosis - a case series and review of the literature","volume":"30","author":"Sandouk","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.eprac.2026.01.753_bib91","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1590\/S1806-37132008001000012","article-title":"Cystic fibrosis-related dyslipidemia","volume":"34","author":"de Alves","year":"2008","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.eprac.2026.01.753_bib92","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/pharmaceutics17030318","article-title":"Evaluation of complex drug interactions between Elexacaftor-Tezacaftor-Ivacaftor and statins using physiologically based pharmacokinetic modeling","volume":"17","author":"Hong","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.eprac.2026.01.753_bib93","series-title":"Uncharted territory: Exploring metabolic dysfunction in the Post-HEM era","author":"Philbrick","year":"2025"},{"key":"10.1016\/j.eprac.2026.01.753_bib94","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings","year":"2008","journal-title":"J Am Diet Assoc"},{"key":"10.1016\/j.eprac.2026.01.753_bib95","doi-asserted-by":"crossref","first-page":"240261","DOI":"10.1183\/16000617.0261-2024","article-title":"Managing an ageing cystic fibrosis population: challenges and priorities","volume":"34","author":"Frost","year":"2025","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.eprac.2026.01.753_bib96","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.3390\/jcm13133652","article-title":"On Behalf Of The Italian Cf Registry Working Group. Nutritional trends in cystic fibrosis: insights from the Italian cystic fibrosis patient registry","volume":"13","author":"Salvatore","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.eprac.2026.01.753_bib97","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jcf.2023.08.004","article-title":"What do people with cystic fibrosis eat? Diet quality, macronutrient and micronutrient intakes (compared to recommended guidelines) in adults with cystic fibrosis-A systematic review","volume":"22","author":"Greaney","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib98","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nut.2015.10.012","article-title":"Body composition and lung function in cystic fibrosis and their association with adiposity and normal-weight obesity","volume":"32","author":"Alvarez","year":"2016","journal-title":"Nutrition"},{"key":"10.1016\/j.eprac.2026.01.753_bib99","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000521241","article-title":"Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement","volume":"15","author":"Donini","year":"2022","journal-title":"Obes Facts"},{"key":"10.1016\/j.eprac.2026.01.753_bib100","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/nu14020310","article-title":"The relationship between body composition, dietary intake, physical activity, and pulmonary status in adolescents and adults with cystic fibrosis","volume":"14","author":"Scully","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.eprac.2026.01.753_bib101","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jcf.2013.11.001","article-title":"Recurrent pulmonary exacerbations are associated with low fat free mass and low bone mineral density in young adults with cystic fibrosis","volume":"13","author":"Alicandro","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib102","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jcf.2007.02.006","article-title":"The influence of body composition on respiratory muscle, lung function and diaphragm thickness in adults with cystic fibrosis","volume":"6","author":"Enright","year":"2007","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib103","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.nut.2009.06.026","article-title":"Fat-free mass depletion in cystic fibrosis: associated with lung disease severity but poorly detected by body mass index","volume":"26","author":"King","year":"2010","journal-title":"Nutrition"},{"key":"10.1016\/j.eprac.2026.01.753_bib104","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.ajcnut.2025.09.019","article-title":"Relationship between skeletal muscle indicators and clinical outcomes in cystic fibrosis is modified by adiposity and CFTR modulator use: a cross-sectional analysis","volume":"122","author":"Gonzalez Ramirez","year":"2025","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.eprac.2026.01.753_bib105","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.1038\/s41598-024-59622-2","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis","volume":"14","author":"Westh\u00f6lter","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.eprac.2026.01.753_bib106","article-title":"Body composition in individuals with cystic fibrosis","volume":"26","author":"Soltman","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.eprac.2026.01.753_bib107","doi-asserted-by":"crossref","first-page":"S352a","DOI":"10.1016\/S1569-1993(25)02215-5","article-title":"599 Baseline body composition and sarcopenia measures of adults with preserved lung function in the STRONG-CF study","volume":"24","author":"Fonseca","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib108","doi-asserted-by":"crossref","first-page":"S405","DOI":"10.1016\/S1569-1993(25)02292-1","article-title":"676 Baseline lean mass deficits in adolescents and adults with CF persist 24\u201330 m following elexacaftor\/tezacaftor\/ivacaftor initiation","volume":"24","author":"Kilberg","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib109","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jcf.2019.01.002","article-title":"Visceral adipose tissue is associated with poor diet quality and higher fasting glucose in adults with cystic fibrosis","volume":"18","author":"Bellissimo","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib110","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.rmed.2013.10.003","article-title":"Association of lung function measurements and visceral fat in men with metabolic syndrome","volume":"108","author":"Thijs","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.eprac.2026.01.753_bib111","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13534","article-title":"Deciphering the \u2018obesity paradox\u2019 in the elderly: a systematic review and meta-analysis of sarcopenic obesity","volume":"24","author":"Liu","year":"2023","journal-title":"Obes Rev"},{"key":"10.1016\/j.eprac.2026.01.753_bib112","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jcf.2023.05.010","article-title":"Nutritional considerations for a new era: a CF foundation position paper","volume":"22","author":"Leonard","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib113","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/s41591-025-03570-5","article-title":"Optimal dietary patterns for healthy aging","volume":"31","author":"Tessier","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.eprac.2026.01.753_bib114","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12890-024-03069-8","article-title":"The long-term effect of Elexacaftor\/Tezacaftor\/Ivacaftor on cardiorespiratory fitness in adolescent patients with cystic fibrosis: a pilot observational study","volume":"24","author":"Stastna","year":"2024","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.eprac.2026.01.753_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2024.105530","article-title":"Effect of aerobic training versus resistance training for improving cardiorespiratory fitness and body composition in middle-aged to older adults: a systematic review and meta-analysis of randomized controlled trials","volume":"126","author":"An","year":"2024","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.eprac.2026.01.753_bib116","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jcf.2023.10.002","article-title":"Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis","volume":"22","author":"Despotes","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.01.753_bib117","first-page":"100391","article-title":"Cholesterol and triglyceride concentrations following 12-18 months of clinically prescribed elexacaftor-tezacaftor-ivacaftor-PROMISE sub-study","volume":"40","author":"Bass","year":"2025","journal-title":"J Clin Transl Endocrinol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26007834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26007834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:57:50Z","timestamp":1784530670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26007834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":117,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1530891X26007834"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.01.753","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aging With Cystic Fibrosis: Endocrine and Metabolic Considerations","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.01.753","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}